InterMune, Inc. and Pharmasset, Inc. to Discuss INFORM-1 Results From EASL Conference, April 25
-- Conference Call and Webcast Scheduled --
BRISBANE, Calif., April 20 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that InterMune and Pharmasset, Inc. will host a live webcast of a discussion of the INFORM-1 results from the EASL conference on Saturday, April 25, 2009, at 7:00 p.m. CEST (1:00 p.m. EDT). Participating in the discussion will be Ed Gane, M.D., principal investigator in the INFORM-1 trial. Members of management from Roche, InterMune and Pharmasset will also be available to answer questions.
Dial-In and Webcast Details
A live webcast and slide presentation will be available through the Investor Relations pages of both InterMune and Pharmasset at www.intermune.com or www.pharmasset.com, respectively. Alternatively, interested parties may access the discussion and ask questions by dialing 888-799-0528 (U.S. & Canada) or 973-200-3372 (International), conference ID # 95452531. A webcast replay will be available approximately three hours after the call and will be archived at www.intermune.com and at www.pharmasset.com.
The companies recommend logging on at least 15 minutes prior to the start of the webcast to ensure adequate time for any software downloads that may be required.
The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S. & Canada) or 706-645-9291 (international), and entering conference ID # 95452531.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
CONTACT: Jim Goff of InterMune, Inc., +1-415-466-2228, email@example.com
Web site: http://www.intermune.com/